S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
OTCMKTS:USRM

U.S. Stem Cell Stock Forecast, Price & News

$0.0086
0.00 (0.00%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
$0.01
50-Day Range
$0.01
$0.01
52-Week Range
$0.01
$0.09
Volume
148,942 shs
Average Volume
2.71 million shs
Market Capitalization
$4.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.65
30 days | 90 days | 365 days | Advanced Chart
Receive USRM News and Ratings via Email

Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter.


U.S. Stem Cell logo

About U.S. Stem Cell

U.S. Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product MyoCell, deals with the clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:USRM
Previous Symbol
NASDAQ:BHRT
Employees
11
Year Founded
N/A

Sales & Book Value

Annual Sales
$280 thousand
Book Value
($0.03) per share

Profitability

Net Income
$-2.89 million
Net Margins
-1,112.03%
Pretax Margin
-1,111.68%

Debt

Price-To-Earnings

Miscellaneous

Free Float
400,541,000
Market Cap
$4.33 million
Optionable
Not Optionable

Company Calendar

Last Earnings
8/07/2019
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
7/15/2022

MarketRank

Overall MarketRank

1.13 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












U.S. Stem Cell (OTCMKTS:USRM) Frequently Asked Questions

How has U.S. Stem Cell's stock been impacted by COVID-19 (Coronavirus)?

U.S. Stem Cell's stock was trading at $0.0061 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, USRM stock has increased by 41.0% and is now trading at $0.0086.
View which stocks have been most impacted by COVID-19
.

Are investors shorting U.S. Stem Cell?

U.S. Stem Cell saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 13,600 shares, an increase of 134.5% from the October 31st total of 5,800 shares. Based on an average trading volume of 4,046,000 shares, the days-to-cover ratio is currently 0.0 days.
View U.S. Stem Cell's Short Interest
.

When is U.S. Stem Cell's next earnings date?

U.S. Stem Cell is scheduled to release its next quarterly earnings announcement on Friday, July 15th 2022.
View our earnings forecast for U.S. Stem Cell
.

How were U.S. Stem Cell's earnings last quarter?

U.S. Stem Cell, Inc. (OTCMKTS:USRM) released its quarterly earnings data on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The business had revenue of $1.30 million for the quarter.
View U.S. Stem Cell's earnings history
.

Who are U.S. Stem Cell's key executives?

U.S. Stem Cell's management team includes the following people:
  • Miguel Tomás, President, CEO, CFO & Director

Who are some of U.S. Stem Cell's key competitors?

What other stocks do shareholders of U.S. Stem Cell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other U.S. Stem Cell investors own include Orion Energy Systems (OESX), Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), (APHA), (AQB), Axsome Therapeutics (AXSM) and (BGSF).

What is U.S. Stem Cell's stock symbol?

U.S. Stem Cell trades on the OTCMKTS under the ticker symbol "USRM."

How do I buy shares of U.S. Stem Cell?

Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is U.S. Stem Cell's stock price today?

One share of USRM stock can currently be purchased for approximately $0.01.

How much money does U.S. Stem Cell make?

U.S. Stem Cell has a market capitalization of $4.33 million and generates $280 thousand in revenue each year.

How many employees does U.S. Stem Cell have?

U.S. Stem Cell employs 11 workers across the globe.

What is U.S. Stem Cell's official website?

The official website for U.S. Stem Cell is www.us-stemcell.com.

Where are U.S. Stem Cell's headquarters?

U.S. Stem Cell is headquartered at 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325.

How can I contact U.S. Stem Cell?

U.S. Stem Cell's mailing address is 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325. The company can be reached via phone at (954) 835-1500, via email at [email protected], or via fax at 954-845-9976.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.